Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models
The Prostate · 2024
DOI: 10.1002/pros.24707 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Sumer Jasmine und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Histone Demethylases, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Genetech DMPK Scholarship, NIGMS NIH HHS.
Abstract (Originalsprache)
Introduction
Lysine‐specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration‐resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive mechanism of resistance in mCRPC patients failing androgen receptor axis‐targeted therapies. Safe and effective LSD1 inhibitors are necessary to determine antitumor response in prostate cancer models. For this reason, we characterize the LSD1 inhibitor bomedemstat to assess its clinical potential in NEPC as well as other mCRPC pathological subtypes.
Methods
Bomedemstat was characterized via crystallization, flavine adenine dinucleotide spectrophotometry, and enzyme kinetics. On‐target effects were assessed in relevant prostate cancer cell models by measuring proliferation and H3K4 methylation using western blot analysis. In vivo, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of bomedemstat are also described.
Results
Structural, biochemical, and PK/PD properties of bomedemstat, an irreversible, orally‐bioavailable inhibitor of LSD1 are reported. Our data demonstrate bomedemstat has >2500‐fold greater specificity for LSD1 over monoamine oxidase (MAO)‐A and ‐B. Bomedemstat also demonstrates activity against several models of advanced CRPC, including NEPC patient‐derived xenografts. Significant intra‐tumoral accumulation of orally‐administered bomedemstat is measured with micromolar levels achieved in vivo (1.2 ± 0.45 µM at the 7.5 mg/kg dose and 3.76 ± 0.43 µM at the 15 mg/kg dose). Daily oral dosing of bomedemstat at 40 mg/kg/day is well‐tolerated, with on‐target thrombocytopenia observed that is rapidly reversible following treatment cessation.
Conclusions
Bomedemstat provides enhanced specificity against LSD1, as revealed by structural and biochemical data. PK/PD data display an overall safety profile with manageable side effects resulting from LSD1 inhibition using bomedemstat in preclinical models. Altogether, our results support clinical testing of bomedemstat in the setting of mCRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Imago Biosciences Inc., A Subsidiary of Merck & Co, Inc., San Francisco, California, USA.
- Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.
- Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
ORCID-Profile: Yuzhuo Z Wang, Samuel R Denmeade, John T Isaacs, W Nathaniel Brennen
Förderung
- NCI NIH HHS
- Genetech DMPK Scholarship
- NIGMS NIH HHS
- US Department of Defense
- PhRMA Foundation Pre-doctoral Fellowship
- Imago BIosciences
- NIH HHS
- European Association for Cancer Research
Zitieren
APA
Jasmine, S., Mandl, A., Krueger, T. E. G., Dalrymple, S. L., Antony, L., Dias, J., Celatka, C. A., Tapper, A. E., Kleppe, M., Kanayama, M., Jing, Y., Speranzini, V., Wang, Y. Z., Luo, J., Trock, B. J., Denmeade, S. R., Carducci, M. A., Mattevi, A., Rienhoff, H. Y., …, & Brennen, W. N. (2024). Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models. The Prostate. https://doi.org/10.1002/pros.24707
Vancouver
Jasmine S, Mandl A, Krueger TEG, Dalrymple SL, Antony L, Dias J, et al. Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models. The Prostate. 2024. doi:10.1002/pros.24707
BibTeX
@article{Jasmine2024,
author = {Jasmine, Sumer and Mandl, Adel and Krueger, Timothy E G and Dalrymple, Susan L and Antony, Lizamma and Dias, Jennifer and Celatka, Cassandra A and Tapper, Amy E and Kleppe, Maria and Kanayama, Mayuko and Jing, Yuezhou and Speranzini, Valentina and Wang, Yuzhuo Z and Luo, Jun and Trock, Bruce J and Denmeade, Samuel R and Carducci, Michael A and Mattevi, Andrea and Rienhoff, Hugh Y and Isaacs, John T and Brennen, W Nathaniel},
title = {Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24707}
}
EUVIMED